# Anecortave Acetate Risk Reduction Trial (AART)

> **NCT00332657** · PHASE3 · TERMINATED · sponsor: **Alcon Research** · enrollment: 36 (actual)

## Conditions studied

- AMD

## Interventions

- **DRUG:** Anecortave Acetate Sterile Suspension, 30 mg/mL
- **DRUG:** Anecortave Acetate Sterile Suspension, 60 mg/mL
- **OTHER:** Anecortave Acetate Vehicle

## Key facts

- **NCT ID:** NCT00332657
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Management Decision
- **Last updated:** 2012-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332657, "Anecortave Acetate Risk Reduction Trial (AART)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00332657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*